Negative association between autoantibodies against IL-17, IL-17/anti-IL-17 antibody immune complexes and destruction in rheumatoid arthritis

Annals of the Rheumatic Diseases

Volumn 75, Issue 7, 2016, Pages 1420-1422

  Ndongo Thiam, Ndieme ^a   Clement, Alice ^a   Pin, Jean Jacques ^b   Razanajaona Doll, Diane ^b   Miossec, Pierre ^a  

^a EDOUARD HERRIOT HOSPITAL   (France)

^b Dendritics   (France)

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 17; INTERLEUKIN 17 ANTIBODY; AUTOANTIBODY; BIOLOGICAL MARKER;

CONTROLLED STUDY; CORRELATIONAL STUDY; DISEASE SEVERITY; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; LETTER; MOUSE; NONHUMAN; NORMAL HUMAN; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN PROTEIN INTERACTION; REGULATORY MECHANISM; RHEUMATOID ARTHRITIS; AGED; ANTIGEN ANTIBODY COMPLEX; CASE CONTROL STUDY; COMPARATIVE STUDY; DISEASE EXACERBATION; FEMALE; IMMUNOLOGY; MALE; METABOLISM; PATHOPHYSIOLOGY; PREDICTIVE VALUE; REFERENCE VALUE; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ANTIGEN-ANTIBODY COMPLEX; ARTHRITIS, RHEUMATOID; AUTOANTIBODIES; BIOMARKERS; CASE-CONTROL STUDIES; DISEASE PROGRESSION; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; INTERLEUKIN-17; MALE; PREDICTIVE VALUE OF TESTS; REFERENCE VALUES; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX;

EID: 84966319188     PISSN: 00034967     EISSN: 14682060     Source Type: Journal    
DOI: 10.1136/annrheumdis-2016-209149     Document Type: Letter

References (9)

1. Nielsen CH, Bendtzen K. Immunoregulation by naturally occurring and disease-associated autoantibodies: Binding to cytokines and their role in regulation of T-cell responses. Adv Exp Med Biol 2012;750:116-32.
2. Jouvenne P, Fossiez F, Banchereau J, et al. High levels of neutralizing autoantibodies against IL-1alpha are associated with a better prognosis in chronic polyarthritis: A follow-up study. Scand J Immunol 1997;46:413-18.
3. Miossec P. Anti interleukin 1alpha autoantibodies. Ann Rheum Dis 2002;61:577-9.
4. Kirkham BW, Kavanaugh A, Reich K. Interleukin-17A: A unique pathway in immune-mediated diseases: psoriasis, psoriatic arthritis and rheumatoid arthritis. Immunology 2014;141:133-42.
5. Ndongo Thiam N, Miossec P. A cell-based bioassay for circulating bioactive IL-17: Application to destruction in rheumatoid arthritis. Ann Rheum Dis 2015;74:1629-31.
6. Hueber W, Patel DD, Dryja T, et al. Effects of AIN457, a fully human antibody to interleukin-17A, on psoriasis, rheumatoid arthritis, and uveitis. Sci Transl Med 2010;2:52-72.
7. Genovese MC, Greenwald M, Cho C S, et al. A phase II randomized study of subcutaneous ixekizumab, an anti-interleukin-17 monoclonal antibody, in rheumatoid arthritis patients who were naive to biologic agents or had an inadequate response to tumor necrosis factor inhibitors. Arthritis Rheumatol 2014;66:1693-704.
8. Miossec P, Kolls JK. Targeting IL-17 and TH17 cells in chronic inflammation. Nat Rev Drug Discov 2012;11:763-76.
9. Burmester GR, Durez P, Shestakova G, et al. Association of HLA-DRB1 alleles with clinical responses to the anti-interleukin-17A monoclonal antibody secukinumab in active rheumatoid arthritis. Rheumatology (Oxford) 2016;55:49-55.